Michael Method

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

Ursula A. Matulonis, Domenica Lorusso, Ana Oaknin et al. · Journal of Clinical Oncology · 2023 · 321 citations · Full text

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny et al. · New England Journal of Medicine · 2023 · 316 citations · Full text

Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology–Gynecologic Oncology Group protocol 240)

Richard T. Penson, Helen Huang, Lari Wenzel et al. · The Lancet Oncology · 2015 · 148 citations · Full text

Advanced Cervical Cancer, Cervical Cancer Management, Patient-reported Outcomes +10

Patient–provider communication and perceived control for women experiencing multiple symptoms associated with ovarian cancer

Heidi Donovan, Ellen M. Hartenbach, Michael Method · Gynecologic Oncology · 2005 · 102 citations

Multiple Symptoms, Family Medicine, Patient Support +10

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

Lucy Gilbert, Ana Oaknin, Ursula A. Matulonis et al. · Gynecologic Oncology · 2023 · 97 citations